PDF herunterladen
Semin Thromb Hemost 2012; 38(04): 404-411
DOI: 10.1055/s-0032-1311993
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Internal Quality Control and External Quality Assurance in Testing for Antiphospholipid Antibodies: Part II—Lupus Anticoagulant

Emmanuel J. Favaloro
1   Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), Pathology West, Westmead Hospital, NSW, Australia
,
Roslyn Bonar
2   RCPA Haematology QAP, Northmead, NSW, Australia
,
Katherine Marsden
3   Pathology, Royal Hobart Hospital, Hobart, Tas, Australia
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
07. Mai 2012 (online)

    Lizenzen und Reprints

Abstract

In addition to the presence of appropriate clinical features, the diagnosis of the antiphospholipid antibody syndrome (APS) fundamentally requires the finding of positive antiphospholipid antibody (aPL) test result(s), with these comprising clot-based assays for the identification of lupus anticoagulant (LA) and immunologic (“solid-phase”) assays such as anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (aβ2GPI). This article is the second of two that review the process for, and provide recommendations to improve, internal quality control (IQC) and external quality assurance (EQA; or proficiency testing) for aPL assays. These processes are critical for ensuring the quality of laboratory test results, and thence the appropriate clinical diagnosis and management of APS. This article covers LA testing. We provide some updated findings from the Royal College of Pathologists of Australasia Haematology Quality Assurance Program, and cover testing results for the past 3 years (2009 to 2011 inclusive). In brief: (1) essentially all laboratories currently perform LA testing using activated partial thromboplastin time (APTT) and dilute Russell viper venom time (dRVVT) methods, and about one-third also employ the kaolin clotting time (KCT); (2) KCT usage has dropped slightly, from around 50% of laboratories in 2009, to around 35% in 2011, presumably reflecting take up of the latest consensus recommendations; (3) other methodologies such as silica clotting time (SCT) and the platelet neutralization procedure (PNP) are only used by <5% of laboratories; (4) interlaboratory coefficients of variation (CVs) are in general moderate, and substantially better than those reported for solid-phase assays such as aCL and aβ2GPI, with median (range) values being 11.6% (9.2 to 25.5%) for APTT ratios, 16.7% (10.1 to 19.2%) for KCT ratios, and 11.7% (5.7 to 17.4%) for dRVVT ratios; (5) CVs increase slightly with increasing LA positivity; (6) most laboratories correctly interpreted test findings for LA, reporting normal samples as normal, and LA-positive samples as positive (albeit with varying gradings of positivity); and (7) however, some laboratories found interpretation to be challenging for some samples, namely a weak LA sample (which was reported as normal by around 50% of laboratories) and a very strong LA sample (which was reported as normal by around 10% of laboratories, primarily those that did not perform mixing studies).

Keywords

lupus anticoagulant - antiphospholipid antibodies - antiphospholipid syndrome - internal quality control - external quality assurance - proficiency testing
 

  • References

  • 1 Asherson RA. The primary, secondary, catastrophic, and seronegative variants of the antiphospholipid syndrome: a personal history long in the making. Semin Thromb Hemost 2008; 34 (3) 227-235
    Thieme ConnectPubMedSuche in Google Scholar
  • 2 Harris EN, Pierangeli SS. Primary, secondary, and catastrophic antiphospholipid syndrome: what's in a name?. Semin Thromb Hemost 2008; 34 (3) 219-226
    Thieme ConnectPubMedSuche in Google Scholar
  • 3 Favaloro EJ, Wong RCW. The antiphospholipid syndrome: a large elephant with many parts or an elusive chameleon disguised by many colours?. Autoimmunity Highlights 2010; 1: 5-14
    CrossrefPubMedSuche in Google Scholar
  • 4 Favaloro EJ, Wong RC. Laboratory testing for the antiphospholipid syndrome: making sense of antiphospholipid antibody assays. Clin Chem Lab Med 2011; 49 (3) 447-461
    CrossrefPubMedSuche in Google Scholar
  • 5 Miyakis S, Lockshin MD, Atsumi T , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (2) 295-306
    CrossrefPubMedSuche in Google Scholar
  • 6 Pengo V, Tripodi A, Reber G , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
    CrossrefPubMedSuche in Google Scholar
  • 7 Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5) 1827-1832
    CrossrefPubMedSuche in Google Scholar
  • 8 Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003; 102 (8) 2717-2723
    CrossrefPubMedSuche in Google Scholar
  • 9 Pengo V, Banzato A, Bison E, Bracco A, Denas G, Ruffatti A. What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?. Semin Thromb Hemost 2012; 38 (4) 322-327
    Thieme ConnectPubMedSuche in Google Scholar
  • 10 Galli M. Interpretation and recommended testing for antiphospholipid antibodies. Semin Thromb Hemost 2012; 38 (4) 348-352
    Thieme ConnectPubMedSuche in Google Scholar
  • 11 Bonar R, Favaloro EJ, Adcock D. Quality in coagulation and haemostasis testing. Biochem Med 2010; 20 (2) 184-199
    PubMedSuche in Google Scholar
  • 12 Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RCW. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part I—anticardiolipin and anti-β2-glycoprotein I antibodies. Semin Thromb Hemost 2012; 38 (4) 390-403
    Thieme ConnectPubMedSuche in Google Scholar
  • 13 Favaloro EJ, Wong RCW. Current clinical and laboratory practice for the investigation of the antiphospholipid syndrome: findings from the 2008 Australasian antiphospholipid antibody survey. Pathology 2009; 41 (7) 666-675
    CrossrefPubMedSuche in Google Scholar
  • 14 Wong RCW, Gillis D, Adelstein S , et al. Consensus guidelines on anti-cardiolipin antibody testing and reporting. Pathology 2004; 36 (1) 63-68
    CrossrefPubMedSuche in Google Scholar
  • 15 Wong RC, Favaloro EJ, Adelstein S , et al. Consensus guidelines on anti-beta 2 glycoprotein I testing and reporting. Pathology 2008; 40 (1) 58-63
    CrossrefPubMedSuche in Google Scholar
  • 16 Wong R, Adelstein S, Gillis D, Favaloro EJ. Development of consensus guidelines for anticardiolipin and lupus anticoagulant testing. Semin Thromb Hemost 2005; 31 (1) 39-48
    Thieme ConnectPubMedSuche in Google Scholar
  • 17 Lakos G, Favaloro EJ, Harris EN , et al. International consensus guidelines on anticardiolipin and anti-β(2) glycoprotein I testing: report from the 13(th) international congress on antiphospholipid antibodies. Arthritis Rheum 2012; 64 (1) 1-10
    CrossrefPubMedSuche in Google Scholar
  • 18 Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8 (12) 2828-2831
    CrossrefPubMedSuche in Google Scholar
  • 19 Bonar R, Favaloro EJ, Zebeljan D , et al. Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP. Pathology 2012; 44 (3) 240-247
    CrossrefPubMedSuche in Google Scholar
  • 20 Favaloro EJ, Bonar R, Sioufi J , et al; RCPA QAP in Haematology. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. Semin Thromb Hemost 2005; 31 (1) 49-58
    Thieme ConnectPubMedSuche in Google Scholar
  • 21 Favaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology 1999; 31 (2) 142-147
    CrossrefPubMedSuche in Google Scholar
  • 22 Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118 (4) 548-557
    CrossrefPubMedSuche in Google Scholar
  • 23 Favaloro EJ, Wong RC, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing. Semin Thromb Hemost 2005; 31 (1) 73-84
    Thieme ConnectPubMedSuche in Google Scholar
  • 24 Favaloro EJ, Wong RCW, Jovanovich S, Roberts-Thomson P. A review of beta2 -glycoprotein-l antibody testing results from a peer-driven multilaboratory quality assurance program. Am J Clin Pathol 2007; 127 (3) 441-448
    CrossrefPubMedSuche in Google Scholar
  • 25 Kershaw G, Suresh S, Orellana D, Nguy Y-M. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38 (4) 375-384
    Thieme ConnectPubMedSuche in Google Scholar
  • 26 Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012; 38 (4) 385-389
    Thieme ConnectPubMedSuche in Google Scholar